Kolon Life Science Inc.
KKRX:10294012,900.00
KRW
-30.00
(-0.23%)
ISIN
KR7102940004
Return %
Stock
S&P 500
1Y
-58.98
14.39
3Y
-50.38
81.42
5Y
-63.09
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seon-Jin Kim
- Full Time Employees
- 454
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- 110 Magokdong-ro Seoul SL South Korea 7793
- IPO Date
- Apr 7, 2009
- Website
- kolonls.co.kr
- Similar Companies
- Business
- Kolon Life Science Inc. (102940.KQ), a biotechnology company founded in 2000 and headquartered in Seoul, South Korea, develops and commercializes cell and gene therapies, active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemicals; it offers contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) services for global pharmaceutical companies, supplies pyrithione antimicrobials (CleanBio) for personal care products such as shampoos, soaps, and wet wipes as well as industrial applications including metalworking fluids and antifouling paints, and provides Kolon BESFLOC water treatment polymers used in chemical, food, pharmaceutical, textile, and sewage treatment industries. The company operates primarily in South Korea with global partnerships and focuses on biopharmaceuticals targeting degenerative arthritis, neuropathic pain, and oncology; its pipeline includes TG-C (formerly Invossa), a first-in-class cell and gene therapy for knee osteoarthritis in Phase 3 clinical trials in the US with BLA submission planned for 2027 and expansions to hip and spinal osteoarthritis, KLS-2031 in Phase 1 for neuropathic pain, KLS-3021 oncolytic viral therapy in preclinical development, and KLS-1020 cancer vaccine. Recent developments encompass a June 2025 $600 million licensing deal granting Juniper Biologics rights to develop and commercialize TG-C for knee osteoarthritis, a process development contract with Kolon TissueGene and Kolon Biotech for TG-C mass production, securing patents for TG-C efficacy evaluation methods in Canada, Indonesia, and seven other countries to bolster commercialization, and KRW 30 billion in funding received from Green E Holdings in 2024 to support operations. Kolon Life Science maintains affiliations within the Kolon Group, including Kolon TissueGene in the US for advanced therapy development and Kolon Pharmaceuticals for prescription drugs in respiratory, dermatology, and orthopedics segments. The company, formerly Korea Tissuegene Asia Ltd. until its January 2006 name change, employs approximately 426 people and trades on the KOSDAQ exchange.